Working to Find a Cure for Charcot-Marie-Tooth: Keith Fargo, PhD

Video

The chief scientific officer of the CMT Research Foundation discussed the foundation’s mission.

“People lose the ability to walk correctly, they begin to fall quite a bit. And then sometimes they lose the use of their hands as well. Braces can really help with keeping people able to do their activities of daily living and everyday tasks. But as of yet, there's really nothing that provides an effective treatment or a cure. And that's what the research foundation is here to provide.”

Charcot-Marie-Tooth disease (CMT) is a rare genetic disease for which no disease-modifying therapies exist today. CMT is a collection of hereditary peripheral neuropathies and those with the different types of CMT experience a gradual weakening of their sensory and motor muscles.

The CMT Research Foundation (CMTRF) was founded to support research that may lead to cures. The CMTRF funds a number of promising projects and research in CMT, many of which are taking cell or gene therapy approaches.

CGTLivespoke with Keith Fargo, PhD, chief scientific officer, CMTRF, to learn more about the CMTRF’s goals and mission. He discussed CMT and its disease burden on patients as well as the unmet needs in the disease.

Recent Videos
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
Related Content
© 2024 MJH Life Sciences

All rights reserved.